Clinical trial results of tucatinib with T-DM1 shows promise in treating HER2+ breast cancer


Phase 1b clinical trial results published in JAMA Oncology show promise for the combination of tucatinib with T-DM1 against heavily pretreated HER2-positive breast cancer. Of 57 patients treated, 48 percent responded to the combination, with cancer control of median 8.2 months.



from Biotech News